Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artefill for HIV-associated Facial Lipoatrophy
NCT02009462Phase 1Completed
- Start
- Dec 2013
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial. Primary endpoints: Long-term safety of Artefill injection volumes at 36 months and Adverse Events at 36 months. Started Dec 2013; status: completed.
Beyond the preview
Go deeper on NCT02009462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009462.